Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Dec 7;19(45):8238-46.
doi: 10.3748/wjg.v19.i45.8238.

Cross-talk between the thyroid and liver: a new target for nonalcoholic fatty liver disease treatment

Yue-Ye Huang  1 , Aaron M Gusdon  1 , Shen Qu  1
Affiliations
Review

Cross-talk between the thyroid and liver: a new target for nonalcoholic fatty liver disease treatment

Yue-Ye Huang et al. World J Gastroenterol. .

Abstract

Nonalcoholic fatty liver disease (NAFLD) has been recognized as the most common liver metabolic disease, and it is also a burgeoning health problem that affects one-third of adults and is associated with obesity and insulin resistance now. Thyroid hormone (TH) and its receptors play a fundamental role in lipid metabolism and lipid accumulation in the liver. It is found that thyroid receptor and its isoforms exhibit tissue-specific expression with a variety of functions. TRβ1 is predominantly expressed in the brain and adipose tissue and TRβ2 is the major isoform in the liver, kidney and fat. They have different functions and play important roles in lipid metabolism. Recently, there are many studies on the treatment of NAFLD with TH and its analogues. We review here that thyroid hormone and TR are a potential target for pharmacologic treatments. Lipid metabolism and lipid accumulation can be regulated and reversed by TH and its analogues.

Keywords: Nonalcoholic fatty liver disease; Obesity; Thyroid hormone; Thyroid hormone receptor.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Yen PM. Physiological and molecular basis of thyroid hormone action. Physiol Rev. 2001;81:1097–1142. - PubMed
    1. Ishizuka T, Lazar MA. The nuclear receptor corepressor deacetylase activating domain is essential for repression by thyroid hormone receptor. Mol Endocrinol. 2005;19:1443–1451. - PubMed
    1. Forrest D, Vennström B. Functions of thyroid hormone receptors in mice. Thyroid. 2000;10:41–52. - PubMed
    1. Katz D, Lazar MA. Dominant negative activity of an endogenous thyroid hormone receptor variant (alpha 2) is due to competition for binding sites on target genes. J Biol Chem. 1993;268:20904–20910. - PubMed
    1. Motomura K, Brent GA. Mechanisms of thyroid hormone action. Implications for the clinical manifestation of thyrotoxicosis. Endocrinol Metab Clin North Am. 1998;27:1–23. - PubMed

MeSH terms

Substances

LinkOut - more resources